A combined laboratory and field evaluation of the Cholestech LDX and CardioChek PA point-of-care testing lipid and glucose analysers

Annals of Clinical Biochemistry

Volumn 51, Issue 1, 2014, Pages 54-67

  Whitehead, Simon J ^a   Ford, Clare ^a   Gama, Rousseau ^a,b  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

Author keywords

Cholesterol; Glucose; Lipids; Point of care testing

Indexed keywords

ASCORBIC ACID; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ANALYZER; ARTICLE; BLOOD ANALYSIS EQUIPMENT; BLOOD SAMPLING; CAPILLARY BLOOD; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HEMATOCRIT; HUMAN; IMMUNOASSAY; INTERRATER RELIABILITY; INTRARATER RELIABILITY; LABORATORY TEST; LIPID ANALYSIS; MEASUREMENT ACCURACY; POINT OF CARE TESTING; POINT OF CARE TESTING ANALYZER; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY; VENOUS BLOOD;

CHOLESTEROL; GLUCOSE; LIPIDS; POINT-OF-CARE TESTING;

ASCORBIC ACID; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; HEMATOLOGIC TESTS; HUMANS; POINT-OF-CARE SYSTEMS; RISK ASSESSMENT;

EID: 84899498212     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563213482890     Document Type: Article

References (45)

1. World Health Organization. Health topics: Cardiovascular diseases, See http://www.who.int/topics/cardiovascular_diseases/en/ (last checked July 2012).
2. Scarborough P, Wickramasinghe K, Bhatnagar P, et al. Trends in Coronary Heart Disease 1961-2011. London, UK: British Heart Foundation, 2011. See http://www.bhf.org.uk/research/statistics.aspx (last checked July 2012).
3. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001; 161: 1717-1723.
4. Fox CS, Coady S, Sorlie PD, et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292: 2495-2499.
5. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in noninsulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823-828.
6. UKPDS Group. UK prospective diabetes study VIII: study design, progress and performance. Diabetologia 1991; 34: 877-890.
7. Harris MI, Klein R, Welborn TA, et al. Onset of NIDDM occurs at least 4-7 years before clinical diagnosis. Diabetes Care 1992; 15: 815-819.
8. Department of Health. Putting Prevention First. NHS Health Check: Vascular Risk Assessment and Management. Best Practice Guidance. London, UK: Department of Health, 2009. See www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_097489 (last checked July 2012).
9. Department of Health. Delivering the NHS Health Check: A Practical Guide to Implementation. A Practical Guide to Point of Care Testing. London, UK: DOH, 2009. See www.improvement.nhs.uk/NHSHealthCheck/LinkClick.aspx? fileticket1/4usgYCuRswjg%3d&tabid1/436 (last checked July 2012).
10. National Cholesterol Education Program Laboratory Standardization Panel. Current status of blood cholesterol measurement in clinical laboratories in the US. Clin Chem 1988; 34: 193-201.
11. National Cholesterol Education Program Laboratory Standardization Panel. Recommendations for Improving Cholesterol Measurement. National Institute for Health Publication No 90-2964. Washington: US Department of Health and Human Services, 1990.
12. Warnick GR and Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary. Clin Chem 1995; 41: 1427-1433.
13. Cholestech Corporation. Total Cholesterol+HDL Cholesterol+Glucose test cassette insert. Cholestech Corporation, 2008.
14. Polymer Technology Systems Inc. PTS Panels: CHOL+HDL+GLU panel test strips insert. Polymer Technology Systems Inc, 2007.
15. Martinello F and da Silva LE. Ascorbic acid interference in the measurement of serum biochemical parameters: in vivo and in vitro studies. Clin Biochem 2006; 39: 396-403.
16. Bland JM and Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
17. Bard RL, Kaminsky LA, Whaley MH, et al. Evaluation of lipid profile measurements obtained from the Cholestech LDX analyzer. J Cardiopulm Rehabil 1997; 17: 413-418.
18. Cobbaert C, Boerma GJ and Lindemans J. Evaluation of the Cholestech L.D.X. desktop analyser for cholesterol, HDL-cholesterol, and triacylglycerols in heparinized venous blood. Eur J Clin Chem Clin Biochem 1994; 32: 391-394.
19. Cummings MH, Watts GF, Mazurkiewicz JC, et al. An evaluation in the diabetes clinic of the Cholestech LDX analyser. Practical Diabetes 1994; 11: 151-153.
20. Shemesh T, Rowley KG, Shepard M, et al. Agreement between laboratory results and on-site pathology testing using Bayer DCA2000+ and Cholestech LDX point-ofcare methods in remote Australian Aboriginal commnities. Clin Chim Acta 2006; 367: 69-76.
21. Jain A, Persaud JW, Rao N, et al. Point of care testing is appropriate for national health service health check. Ann Clin Biochem 2011; 48: 159-165.
22. Batki AD, Holder R, Thomason HL, et al. MDA Evaluation Report: Cholestech LDX Lipid Analyser.Birmingham, UK: Medical Devices Agency, 1995.
23. Volles DF, McKenney JM, Miller WG, et al. Analytic and clinical performance of two compact cholesterol-testing devices. Pharmacotherapy 1998; 18: 184-192.
24. Gialamas A, Laurence CO, Yelland LN, et al. Assessing agreement between point of care and laboratory results for lipid testing from a clinical perspective. Clin Biochem 2010; 43: 515-518.
25. Batki AD, Holder R, Hughes E, et al. Polymer Technology Systems CardioChek PA Lipid System. Birmingham, UK: Wolfson Research Laboratories, 2005.
26. Stein JH, Carlsson CM, Papcke-Benson K, et al. Inaccuracy of lipid measurements with the portable Cholestech LDX analyzer in patients with hypercholesterolemia. Clin Chem 2002; 48: 284-290.
27. Mendez-Gonzalez J, Bonet-Marques R and OrdonezLlanos J. Lipid profile in ambulatory subjects using 3 point-of-care devices and comparison with reference methods. Point of Care 2009; 8: 102-107.
28. Panz VR, Raal FJ, Paiker J, et al. Performance of the CardioChek PA and Cholestech LDX point-of-care analysers compared to clinical diagnostic laboratory methods for the measurement of lipids. Cardiovasc J S Afr 2005; 16: 112-117.
29. Shephard MDS, Mazzachi BC and Shephard AK. Comparative performance of two point-of-care analysers for lipid testing. Clin Lab 2007; 53: 561-566.
30. Dale RA, Jensen LH and Krantz MJ. Comparison of two point-of-care lipid analyzers for use in global cardiovascular risk assessments. Ann Pharmacother 2008; 42: 633-639.
31. Taylor JR and Lopez LM. Cholesterol: point-of-care testing. Ann Pharmacother 2004; 38: 1252-1257.
32. Pluddemann A, Thompson M, Price CP, et al. Pointof-care testing for the analysis of lipid panels: primary care diagnostic technology update. Br J Gen Pract 2012; 62: e224-e226.
33. Cramb R, French J, Mackness M, et al. Lipid external quality assessment: commutability between external quality assessment and clinical specimens. Clin Chem 2008; 45: 260-265.
34. Langlois MR and Blaton VH. Historical milestones in measurement of HDL-cholesterol:Impact on clinical and laboratory practice. Clin Chim Acta 2006; 369: 168-178.
35. Warnick GR, Nauck M and Rifai N. Evolution of methods for measurement of HDL-cholesterol: from ultracentrifugation to homogeneous assays. Clin Chem 2001; 47: 1579-1596.
36. Blumfield TA, Hertelendy WG and Ford SH. Simultaneously obtained skin-puncture serum, skinpuncture plasma, and venous serum compared, and effects of warming the skin before puncture. Clin Chem 1977; 23: 1705-1710.
37. Gambino R. Glucose: a simple molecule that is not simple to quantify. Clin Chem 2007; 53: 2040-2041.
38. Mikesh LM and Bruns DE. Stabilization of glucose in blood specimens: mechanism of delay in fluoride inhibition of glycolysis. Clin Chem 2008; 54: 930-932.
39. Labib M, Digger T and Perks D. Reagent-strip glucose methods and haematocrit. Lancet 1990; 335: 973-974.
40. Stringer MS and Mackenzie JM. How reliable are blood glucose meter measurements? Clin Biochem Revs 1990; 11: 134.
41. Weiner K. The effect of haematocrit on reagent strip test for glucose. Diab Med 1991; 8: 172-175.
42. Harmelin D, Robin H, Molyneaux L, et al. Reflectance meter type and management of gestational diabetes. Lancet 1990; 335: 735-736.
43. Martinello F and da Silva LE. Mechanism of ascorbic acid interference in biochemical tests that use peroxide and peroxidase to generate chromophore. Clin Chim Acta 2006; 373: 108-116.
44. Martinello F and da Silva LE. Ascorbic acid interference in the measurement of serum biochemical parameters: in vivo and in vitro studies. Clin Biochem 2006; 39: 396-403.
45. Medicines and Healthcare products Regulatory Agency. Document DB2010 (02) Management and Use of IVD Point of Care Test Devices. MHRA, 2010. www.mhra.gov.uk/Publications/Safetyguidance/Device/Bulletins/CON071082.